At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pivotal, Prospective, Open-Label, Multicenter Paired Comparison Study Of SentiMag/SiennaXP And The Standard Of Care In Patients With Breast Cancer Who Are Undergoing Lymph Node Mapping As Part Of A Sentinel Node Biopsy Procedure
In Brief
A clinical study evaluating SiennaXP, Technetium Tc99m Sulfur Colloid, and 1 other intervention for Breast Cancer. Completed, enrolled 160 participants across 6 sites.
Detailed Summary
The purpose of this pivotal study is to provide prospective evidence that the SentiMag®/SiennaXP® is safe and non-inferior to the current standard of care for lymph node localization in patients with breast cancer as part of a sentinel lymph node biopsy (SLNB) procedure and to summarize measures of product safety and performance.
Study Details
Timeline
Interventions
Sub-cutaneous injection of SiennaXP magnetic marker, followed by lymph node localization using the SentiMag handheld magnetic probe
Injection of a single dose of radioisotope (Technetium Tc99m Sulfur Colloid)
Injection of a single dose of isosulfan blue dye